Anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer

A method of treating non-small cell lung carcinoma (NSCLC) in a human patient, comprising administering MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof to the patient, wherein the dose of MEDI4736 or an antigen-binding fragment thereof is 20-fold the dose of tremelimumab or an antigen-binding fragment thereof, wherein the MEDI4736 or an antigen-binding fragment thereof is administered about 1 hour following administration of tremelimumab or an antigen-binding fragment thereof, wherein the MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof are administered every 4 weeks for at least up to 16 weeks, and wherein the dose of MEDI4736 or an antigen-binding fragment thereof is 1500 mg and the dose of tremelimumab or an antigen-binding fragment thereof is 75 mg.